Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study
Table 2
Treatment regimens with various drug combinations in patient groups based on different disease durations.
Characteristics
All patients with AS (n=958)
Duration≤5 years (n=305)
Duration>5 years and ≤10 years (n=332)
Duration >10 years (n=321)
P valu
NSAIDs, %
98.2
97.7
99.1
97.8
0.329
TNFi, %
20.8
18.7
22.3
21.2
0.522
csDMARDs, %
66.4
65.6
68.1
65.4
0.723
Sulfasalazine
25.2
32.8
25.6
17.4
0.001
Leflunomide
13.5
15.1
13.0
12.5
0.595
Methotrexate
3.3
5.2
2.7
2.2
0.075
Thalidomide
23.7
13.8
25.0
31.8
<0.001
TCM, %
62.4
61.0
63.0
63.2
0.819
Treatment regimen, %
NSAIDs monotherapy
22.5
26.0
20.3
21.6
TNFi monotherapy
0.6
1.0
0.3
0.6
NSAIDs + csDMARDs
56.3
54.6
57.9
56.2
NSAIDs + TNFi
10.3
7.2
11.5
11.9
NSAIDs + TNFi + csDMARDs
9.5
10.2
10.0
8.4
AS: ankylosing spondylitis; NSAIDs: nonsteroidal anti-inflammatory drugs; TNFi: TNF inhibitors; csDMARDs: conventional synthetic disease modifying antirheumatic drugs; TCM: traditional Chinese medicine. P < 0.05.
